Anticoagulant-induced prothrombin deficiency

Anticoagulant-induced prothrombin deficiency is an acquired coagulopathy characterized by clinically significant depletion or functional impairment of prothrombin (factor II) and related vitamin K–dependent clotting factors The resulting systemic hypoprothrombinemia impairs thrombin generation, marked by a prolongation of prothrombin time and the international normalized ratio, and confers a heightened risk for minor to life-threatening hemorrhage

Anticoagulant-induced prothrombin deficiency is an acquired coagulopathy characterized by clinically significant depletion or functional impairment of prothrombin (factor II) and related vitamin K–dependent clotting factors Pathophysiologically, these pharmacologic agents inhibit vitamin K epoxide reductase, blocking the hepatic gamma-carboxylation necessary to produce functional coagulation factors

Anticoagulant-induced prothrombin deficiency is an acquired coagulopathy characterized by clinically significant depletion or functional impairment of prothrombin (factor II) and related vitamin K–dependent clotting factors This clinical state develops as an intended effect, supra-therapeutic consequence, or toxicity in individuals receiving vitamin K antagonist anticoagulants, primarily coumarin derivatives such as warfarin or indanedione derivatives

This clinical state develops as an intended effect, supra-therapeutic consequence, or toxicity in individuals receiving vitamin K antagonist anticoagulants, primarily coumarin derivatives such as warfarin or indanedione derivatives The resulting systemic hypoprothrombinemia impairs thrombin generation, marked by a prolongation of prothrombin time and the international normalized ratio, and confers a heightened risk for minor to life-threatening hemorrhage